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ABSTRACT A theory based on the Smolukowski analysis of colloid stability shows that the presence of charged, surface-active
serum proteins at the alveolar air-liquid interface can severely reduce or eliminate the adsorption of lung surfactant from the sub-
phase to the interface, consistent with the observations reported in the companion article (pages 1769–1779). Adding
nonadsorbing, hydrophilic polymers to the subphase provides a depletion attraction between the surfactant aggregates and the
interface, which can overcome the steric and electrostatic resistance to adsorption induced by serum. The depletion force
increaseswith polymer concentrationaswell aswith polymermolecularweight. Increasing thesurfactant concentrationhasamuch
smaller effect than adding polymer, as is observed. Natural hydrophilic polymers, like the SP-A present in native surfactant, or
hyaluronan, normally present in the alveolar ﬂuids, can enhance adsorption in the presence of serum to eliminate inactivation.
INTRODUCTION
Under normal conditions, the mixture of lipids and proteins
in lung surfactant quite reliably lowers the interfacial tension
in the lungs to nearly zero on exhalation, thereby insuring a
negligible work of breathing and uniform lung inﬂation (1,2).
The absence of lung surfactant in premature infants leads to
neonatal respiratory distress syndrome (NRDS), which can
be treated by delivering replacement surfactants, often derived
from animals, to the lungs. Such surfactants often provide
immediate relief from symptoms and improved oxygenation
and gas exchange (1,2). However, there are certain cases,
meconium aspiration syndrome being one example, in which
surfactant therapy is less effective because substances not
normally present in the alveolar ﬂuid inactivate surfactant,
leading to a decreased ability to reduce surface tension to the
levels necessary for proper lung function (2–5).
Surfactant inactivation is also thought to be one factor
in the development of acute respiratory distress syndrome
(ARDS), which affects both adults and children (2,6–8). Ex-
tracted bronchial ﬂuid (lavage) from ARDS patients shows
elevated levels of serum and inﬂammatory proteins (2,9,10)
and the ratio of soluble protein to lung surfactant in lavage
correlates with severity and outcome in ARDS (11). ARDS
lavage also has a reduced surface activity both in terms of the
speed with which it adsorbs to an exposed air-water interface
and the minimum surface tension at a given compression (9).
Biophysical studies of lung surfactant mixed with serum
proteins show that, at sufﬁciently high protein concentra-
tions, ARDS-like depression of surfactant surface activity is
obtained (2,6,12). Recent clinical reports (13,14) conﬁrm
earlier in vitro experiments (6) showing that high, 300–
500 mg/kg doses of bovine extract surfactant (relative to the
;100 mg/kg typically given for NRDS treatment) delivered
directly to the lung via bronchoscope signiﬁcantly improved
oxygenation in patients with ARDS (14), and decreased
expected patient mortality. In a second study, large volumes
of surfactant were administered by bronchoscope, followed
by removal of at least 50% of the volume instilled. This study
found that the ﬂuid removed contained large amounts of
inﬂammatory and serum proteins (15). These studies suggest
that increasing the exogenous surfactant pool, while at the
same time, lowering the protein load in the alveoli, could im-
prove results for ARDS patients (6).
This recent work contributes to the general consensus that
serum proteins, inﬂammatory agents, and other surface-active
species not normally found in the lung can be a signiﬁcant
factor in the inactivation of lung surfactant, and hence, may
be involved in the development of ARDS. As serum proteins
inactivate both endogenous and replacement lung surfactants
in vitro, serum proteins likely also reduce replacement
surfactant efﬁcacy in NRDS (6,9,12,16). Unfortunately, the
mechanism of lung surfactant inactivation by serum proteins
has remained obscure, frustrating efforts to rationally con-
struct surfactant formulations appropriate for ARDS.
In the companion article (pages 1769–1779), we showed
that serum proteins in the subphase greatly reduce or even
eliminate the normal adsorption of clinical lung surfactants
to the air-water interface at low surface pressures. Surfactant
spread via organic solution directly onto the air-water
interface was not affected by serum. Hence, reduced
surfactant adsorption from bilayer aggregates in the subphase
to a serum-covered interface is one cause of rapid surfactant
inactivation. The diminished quantity of surfactant at the
interface means that the surface tension is higher than normal
for a given compression of the interface during exhalation.
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Hence, the low surface tensions required for proper lung
function may never be reached (12).
As shown in the companion article and elsewhere (3–5,
16–23), ionic or nonionic polymers added to clinical and
model surfactants (without SP-A) enhance surface activity
and reduce surfactant inactivation in vitro and in vivo.
Dextrans, polyethylene glycol (PEG) and natural hyaluronic
acid (HA) restore the normal rates of surfactant adsorption
in the presence of serum. Neither serum nor polymers in the
subphase have an effect on the equilibrium spreading pres-
sure of the surfactant or the collapse pressure (12). Polymer
added to surfactants with no serum present also increased
the rate of adsorption (17), but not the equilibrium spreading
pressure or the collapse pressure of the surfactant. Hence, the
origin of surfactant inactivation by serum proteins and
reversal by hydrophilic polymers is likely the enhanced
adsorption of surfactant due to the polymer induced
depletion force (24,25) overcoming the reduction of surfac-
tant adsorption by the electrostatic and steric repulsion from
serum proteins at the interface.
To explain the results of the companion article, as well as
develop a model for surfactant inactivation in ARDS, we
present a quantitative theory of surfactant adsorption based
on the classical Smolukowski analysis of colloid stability
(26). The result shows that the presence of charged, surface-
active serum proteins at the alveolar air-liquid interface,
below the maximum surface pressure of the serum proteins,
pmax (12,27), can induce a repulsive energy barrier to
surfactant transport to the interface, severely reducing or
even eliminating the amount of lung surfactant at the
interface. Similar to the work of Hall and co-workers (28),
we have divided the adsorption process into two steps: 1),
transport from the subphase to the interface, followed by 2),
conversion from bilayer aggregates to interfacial ﬁlm. This
theory examines only the ﬁrst step in the process: transport.
The reduction in adsorption is due to a combination of steric
and electrostatic repulsive interactions caused by the
presence of serum proteins at the interface (29), consistent
with the observations reported in the companion article.
The enhanced adsorption of surfactant in the presence of
hydrophilic polymers can be explained within the same
theory by adding a simple ‘‘depletion attraction’’ term to the
interaction potential (22,24,25,30–32). The surfactant ag-
gregates are pushed toward the interface by an osmotic
pressure induced by the exclusion of the polymer from the
‘‘excluded volumes’’ of the surfactant aggregates and the
interface. The depletion attraction is sufﬁciently strong that it
can overcome the electrostatic and steric repulsion imposed
by the serum at the interface. The increased surfactant ad-
sorption helps to drive the serum from the interface, resulting
in a reversal of the inactivation. The depletion attraction
model also explains why high molecular weight, anionic
polymers like HA can reverse inactivation at lower weight
fractions than neutral, lower molecular weight polymers like
PEG, as was shown in the companion article.
The serum protein induced energy barrier to
surfactant adsorption
Hall and co-workers (28) have outlined a two-step process
for transfer of surfactant lipids from the subphase to the air-
liquid interface. The ﬁrst step is the transport of surfactant
aggregates from the bulk solution to the interface. The
second step, the conversion from bilayer structures to surface
monolayer, is affected by the acyl group composition of
the lipids and the surfactant proteins. Monolayer surface
spreading does not appear to be rate limiting in Hall’s
experiments, which do not include inhibition of adsorption
or application of surfactants directly onto liquid surfaces
(28). From our experiments, the rate of surfactant adsorption
is primarily affected below pmax of the serum, which sug-
gests that the conversion from bilayer to monolayer is not
affected signiﬁcantly by serum. Rather, it is the transport of
surfactant to the interface that is inhibited by serum and re-
versed by the addition of polymers.
The surface pressure exerted by a surface active, soluble
protein (or any other species) is typically a logarithmic func-
tion of concentration up to a certain bulk concentration at
which the surface becomes saturated (26,27,33–35). The
serum protein concentrations used in the companion article
exerted surface pressures of 10–20 mN/m; the maximum
surface pressure of serum is ;24 mN/m at saturation and
higher concentrations (27). This relationship between in-
hibition and surface activity appears to hold for nonprotein
inhibitors as well. Lysophosphatidylcholine is a more potent
inhibitor than serum; the surface pressure at the surface
saturation concentration is 34 mN/m, which is signiﬁcantly
greater than serum (36). From a variety of experiments,
inactivation of surfactant occurs when a surface active
species not normally present in the alveoli, such as albumin,
serum, lysolipids, etc., compete successfully for the air-water
interface with lung surfactant (6,12). Most of these species are
water soluble and rapidly adsorb to the air-water interface to
produce moderate (20–34 mN/m) maximum surface pres-
sures, pmax. However, as the interfacial area is reduced
during exhalation, these soluble molecules at the interface
can exchange with the subphase much more easily than lung
surfactants. Hence, the surface pressure rises much more
slowly with compression than for a surfactant-covered
interface and surface pressures greater than pmax cannot be
maintained for long because the serum is sufﬁciently soluble
to leave the interface. A certain hysteresis of the surface
pressure on compression of serum or albumin is observed;
a fast compression will cause the surface pressure to rise, but
it rapidly returns to the saturation surface pressure once the
fast compression ends.
The lipids and hydrophobic proteins in lung surfactant are
essentially insoluble as molecular species in the subphase; lung
surfactants exist at the air-water interface as monolayer or
multilayer ﬁlms, as bilayer aggregates in the subphase, or
as some intermediate structure (such as the tubular myelin
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surfactant (2) that forms during the conversion of lung
multilamellar bodies after secretion from the type II cell into
the alveolar hypophase (37)). The energy difference between
surfactant in the subphase and at the interface determines the
equilibrium spreading pressure, pe of the surfactant; pe is
directly related to the surface concentration of the surfactant
at equilibrium. However, when surfactant ﬁlms are compressed,
the surface pressure increases well above pe until the ﬁlm
collapses, generally by the generation of folds, cracks, etc.,
in the ﬁlm (38–40). The maximum surface pressure of the
surfactant ﬁlm is set by this collapse pressure, and the surface
pressure can remain at levels well above pe even without fast
compression. Proper lung function requires that the surface
tension in the alveoli drop to near zero as the alveolar surface
area decreases, which requires a high collapse pressure and
an interface densely packed with surfactant. Mixed surfactant-
serum ﬁlms require greater compression to reach the maxi-
mum surface pressure because the serum is constantly being
removed from the monolayer at pressures above pmax.
Hence, the combined ﬁlm never reaches the low surface ten-
sions necessary for proper lung function, and breathing be-
comes more difﬁcult (6,41).
The rate of adsorption from subphase to interface deter-
mines the relative amount of surfactant versus inhibitor at
the interface. As surfactant is in large aggregates that must
undergo structural rearrangements during and after ad-
sorption (28,37,42), surfactant adsorption is slow com-
pared to inhibitor adsorption. Hence, if an inhibitor is
present in the subphase, the inhibitor will adsorb rapidly up
to pmax (12) as shown in the companion article; when
serum is added to the subphase the minimum surface
pressure remains between 10–18 mN/m.
In the companion article we found that serum present at
the air-water interface slows or stops adsorption of surfactant
belowpmax, although there is much less effect on adsorption
above pmax. This suggests that the serum components at the
interface must be pushed aside for surfactant to be adsorbed
belowpmax and that the serum proteins are removed from the
interface at surface pressures above pmax. In addition to
this steric barrier to adsorption, serum components and the
phosphatidylglycerol, phosphatidylserine, and fatty acid
components of lung surfactant are negatively charged. The
electrostatic double layer induced by the charges provides
an additional longer-ranged potential that repels surfactant
aggregates (33). The anionic lipids are usually located in
domains within the monolayer along with the cationic
surfactant speciﬁc proteins SP-B and SP-C (38,43,44).
The net interaction of the surfactant monolayer with the
surfactant aggregate may be attractive due to the proper
mixture of cationic proteins and anionic lipids, and is likely
purely repulsive when purely anionic serum proteins occupy
the interface due to a less-than-optimal balance of charge
(45). Surfactant appears to need to encounter either a free or
surfactant-covered interface to optimize surfactant adsorp-
tion.
Energy barriers and adsorption
An analysis similar to the classical Smoluchowski model of
colloid aggregation can be derived to quantify the effect of
the serum proteins at the interface (26,46). Fick’s ﬁrst law
of diffusion states that the ﬂux/area, J ¼ dG=dt; to an
interface located at x ¼ 0, is proportional to a friction factor,
D=kBT (D is the diffusion constant for the surfactant ag-
gregate, T is the absolute temperature, kB is Boltzmann’s
constant, G is the surface concentration), the bulk surfactant
concentration, C, and the driving force, which in general, is
the gradient in chemical potential, (@m=@x) (26):
dG
dt
¼ J ¼  D
kBT
C
@m
@x
: (1)
The chemical potential of an ideal solution in an external
potential, V(x), where x is the distance from the interface is:
m ¼ mo1 kBT lnC1VðxÞ: (2)
V(x) may be due to electrostatic forces, the steric work
needed to push aside the serum, the depletion attraction, etc.
Combining Eqs. 1 and 2 leads to a general diffusion equa-
tion:
J
D
¼ dC
dx
1
C
kBT
dV
dx
: (3)
Under steady-state conditions, the ﬂux/area, J, is constant,
and Eq. 3 can be integrated by multiplying both sides by
expðV=kBT) (26):
J
D
exp
V
kBT
¼ exp V
kBT
dC
dx
1
C
kBT
dV
dx
 
¼ d
dx
C exp
V
kBT
 
;
(4)
which is integrated as follows:
J
D
Z N
0
exp
V
kBT
dx ¼
Z CB
0
d C exp
V
kBT
 
: (5)
The limits of integration are taken to be such that the sur-
factant concentration is zero anytime a surfactant aggregate
gets to the interface, (C ¼ 0 at x ¼ 0, this assumes that
conversion from bilayer aggregate to interfacial ﬁlm is fast
compared to the transport to the interface), and the con-
centration reaches the bulk concentration, C ¼ CB, and far
from the interface, the potential, V ¼ 0, as x/N: This is an
idealization of the real situation, and assumes that the slow
step in adsorption is transport of surfactant past the barrier,
rather than conversion of surfactant from bilayer to mono-
layer (28). Integrating the right-hand side of Eq. 5 gives:
Z CB
0
d C exp
V
kBT
 
¼ CB: (6)
The integral on the left-hand side of Eq. 5 is approximated
by noting that the exponential term is dominated by the value
of V at its maximum, Vmax, and the potential can be expanded
in a Taylor series about the maximum:
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V ﬃ Vmax1 dVmax
dx
ðx  xmzxÞ1 d
2
Vmax
dx
2
ðx  xmaxÞ2
2
1 . . . :;
(7)
atVmax, the ﬁrst derivative is zero. Combining Eqs. 6–8 gives:
CB ¼ J
D
exp
Vmax
kBT
Z N
0
exp
d
2
Vmax
dx2
ðx  xmaxÞ2
2
kBT
dx: (8)
In Eq. 8, the integrand is simply a Gaussian and gives:
CB ¼ Jp
0:5
2Dp
exp
Vmax
kBT
p
2 ¼ d
2
Vmax
dx
2

2kBT; (9)
where p is roughly constant, and reﬂects the shape of the po-
tential around the maximum, and has units of length1 (in Eqs.
9–11,p is 3.1416, not the surface pressure). Rearranging Eq. 9,
J ¼ 2DCBp
p
0:5 exp
Vmax
kBT
: (10)
Equation 10 shows that the ﬂux is proportional to the bulk
concentration and the negative exponential of the potential
maximum.
We can approximate Vmax ﬃ ðE1  E0Þ1pDA1Eelect near
the maximum of the interaction potential. E1  E0 is the
energy difference between surfactant in bilayers and in the
monolayer, which leads to adsorption onto a clean interface
with zero surface pressure. pDA is the work required to clear
an area of already-occupied interface with surface pressure
p to give the surfactant room to adsorb. Eelect accounts for
the electrostatic repulsion between a charged interface and
the anionic surfactants (29,33).
If the concentration near the interface is depleted by ad-
sorption, a boundary layer will form, which causes the
effective concentration to be decreased as CB ¼ Co=ðDtÞ0:5
as the boundary layer thickness grows. Combining all these
terms together, lumping the unknown constants into an effec-
tive diffusivity gives a general expression for adsorption to
an interface in the presence of an energy barrier.
dG
dt
¼J ¼Co Deff
pt
 1=2
exp ðE1E01pDA1EelectÞ=kBT½ :
(11)
If there is no surfactant depletion, or if the subphase is well
mixed, Deff=ðptÞ0:5 is replaced by Deff=x; in which x is the
diffusion boundary layer thickness (47). The adsorption to
the interface depends primarily on the magnitude of the po-
tential maximum due to the exponential. The decrease in the
rate of adsorption due to the presence of the potential barrier
imposed by the serum is:
Jserum
J
¼ exp ðpmaxDA1EelectÞ=kBT½ : (12)
Hence, if an inhibitor has already adsorbed to the interface,
there is a minimum surface pressure of pmax, the interface is
charged, and the rate of surfactant adsorption slows due to the
barrier. The energy barrier may be sufﬁciently large that on
experimental timescales, insufﬁcient surfactant adsorbs to the
interface to raise the surface pressure above pmax to displace
the serum (see Figs. 4–6). To stabilize colloidal particles
indeﬁnitely against equilibrium aggregation, the energy barrier
height need only be ;15 kBT (26,33). For the relatively fast
cycles of expansion and compression under normal breathing,
the energy barrier likely does not have to be even that high to
effectively prevent sufﬁcient surfactant adsorption for proper
lung function. Doubling the surfactant concentration, Co, in
Eq. 11 will not have nearly the effect of reducing the potential
barrier by 50%, i.e., reducing pmaxDA1Eelect from 10 to
5 kBT. Equation 11 predicts the increased rate of lipid ad-
sorption and respreading after monolayer collapse that results
fromdecreasing the electrostatic potential,Eelect by increasing
the salt concentration of the subphase, and hence the Debye
length as shown in Alig et al. (29).
Effects of polymers: lowering the energy barrier
Enhancing the rate of surfactant adsorption in the presence of
serum or other charged proteins requires that the energy
barrier in Eq. 11 be lowered. Although it is possible to lower
Eelect by increasing the salt concentration in the subphase in
vitro (29), this would not be practical in vivo as it could lead
to edema. A second possibility would be to reduce the serum
concentration at the interface (15); however, due to the log-
arithmic dependence of surface pressure on the serum con-
centration, a substantial fraction of the protein would have to
be removed to see an effect.
However, adding hydrophilic, nonadsorbing polymers to
the subphase creates a force of entropic origin that pushes the
surfactant aggregates to the interface and can provide the
necessary attractive potential to enhance adsorption. A mix-
ture of two different sizes of noninteracting ‘‘hard spheres’’
maximizes its entropy by maximizing the volume accessible
per ‘‘sphere’’ (24,25,30–32). Here, the small spheres are the
polymers with radius of gyration, Rg (typically nm), and the
large spheres are surfactant aggregates of radius R (typically
microns). The polymer is sterically excluded from the regions
where the aggregates come within Rg of each other or the
interface (shaded regions in Fig. 1). As the large spheremoves
toward another large sphere or the wall, the volumes excluded
from the small spheres (Fig. 1) overlap, causing the total
volume accessible to the small spheres to increase (small box
in right corner) (24,25,30–32). This increases the total en-
tropy of the mixture (decreases the free energy) by an amount
proportional to the size of the excluded volume overlap re-
gion, multiplied by the osmotic pressure of the small spheres.
The depletion potential, W(l), as a function of separation, l,
between the large sphere and the rigid wall (32) is:
WðlÞ ¼3fpkBT
R
Rg
1 l
2Rg
 2
; (13)
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for l , 2Rg  R, and W(l) ¼ 0 otherwise; fp is the volume
fraction of polymer, kB is Boltzmann’s constant, and T is the
temperature (25). Moving a single large sphere to a rigid
surface decreases the mixture’s free energy by 3ðR=RgÞfp
kBT: If the surface or the sphere deforms, an even larger
excluded volume overlap region can result, with a larger
force pushing the large sphere toward the surface (25). The
depletion potential is independent of the chemistry of the
large and small spheres, as long as the polymer does not
adsorb to surfactant or interface. The increase in the ﬂux to
the interface is proportional to
Jserum1polymer
Jserum
¼ exp ðWðlÞÞ=kBT½ : (14)
The depletion interaction effectively ‘‘pushes’’ the surfactant
to the interface (Fig. 1). For the volume fractions (fp ; 1–
10%) and aspect ratios (R/Rg ; 10–300) that reduce inhibi-
tion, W(l) ; 10–100 kBT (3–5,16,18,19,22,23,48,49). The
range of the depletion force is twice the radius of gyration of
the polymer, which is comparable to the range of elec-
trostatic forces in physiological saline,;1–5 nm (26) for the
10–1250 kDA polymers used in the experiments in the
companion article. Adding the polymer lowers Vmax by an
amount proportional to W(l), providing an exponential
increase in the rate of surfactant adsorption, thereby
reversing the effects of inhibition. Yu et al. (22) have shown
that increasing the PEG concentration increases the rate of
adsorption of surfactant even in the absence of inhibitors,
consistent with the predictions of Eq. 14.
Fig. 2 shows that the depletion forces between surfactant
aggregates can push aggregates together against electrostatic
repulsion and thermal motion to form large ﬂocs. W  1:5
ðR=RgÞfpkBT between two spheres because of the smaller
excluded volume overlap (25), half that between a sphere
and a surface. Infasurf, Curosurf, and Survanta form large
ﬂocs when 5 wt% 10 kDa PEG is added to the buffer, which
conﬁrms that the depletion interaction is large compared to
thermal motions (kBT) and large compared to any electro-
static repulsion between the anionic surfactant particles
(26,33). Aggregation of surfactant particles after polymer
addition was also observed by Yu et al. (22) and was as-
cribed to depletion attraction. Hence, it is clear that the de-
pletion attraction is capable of overcoming the electrostatic
repulsions and thermal motions in physiological salt con-
ditions and should signiﬁcantly lower the barrier to sur-
factant adsorption.
Molecular weight and polymer charge: optimizing
surfactant formulations
The magnitude of the depletion interaction, and hence the
increase in adsorption, can be controlled by changing the sur-
factant volume fraction and/or the aspect ratio of the sur-
factant to the polymer. For a polymer in a good solvent, such
as PEG in water, Rg scales as M
0.6 (33), in which M is the
polymer molecular weight. For highly charged polyelectro-
lytes like hyaluronic acid, Rg can vary from M
0.6 to M1.0
depending on the charge distribution of the polymer and
the ionic strength of the solution. Hence, for PEG, the
depletion potential can be expressed as:W }RNpM1:2=V: Np
is the number of polymer chains in a volume, V. For HA, the
scaling with molecular weight is more complex, W }RNp
M1:22:0=V: In most experiments regarding inhibition, the
polymer concentration is expressed as a weight of polymer
per unit volume, r ¼ NpM/V (3,4,16,20–23,48). The mo-
lecular weight dependence of inhibition reversal has not been
systematically explored, although this simple argument
suggests that higher molecular weight polymers should
reduce inhibition at lower weight/volume ratios than low
molecular weight polymers. This is consistent with our ex-
periments that show it required 5 wt/v 10 kDa PEG to
FIGURE 1 Origin of depletion forces in a binary sphere mixture. (Top)
The centers of the small spheres are excluded from the hatched regions
within one small sphere radius (Rg) of the larger spheres (radius R) or the
interface. (Bottom) When the larger spheres move to the interface or toward
each other, the hatched regions overlap, and the total volume accessible to
the small spheres increases by this amount (small volume in the bottom
right-hand corner). The increase in the volume accessible to the polymer
increases the entropy of the system, resulting in a net force pushing the large
spheres toward the interface or each other.
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provide similar inhibition reversal as .125 wt/v 1240 kDa
hyaluronic acid. From the scaling arguments, to provide the
same depletion attraction, (rPEG=rHAÞ¼ðM0:21:0HA Þ=ðM0:2PEGÞ
3 750;which spans the experimental value of;40. Yu et al.
(22) have also shown that adsorption is increased for a given
weight/volume of PEG as the molecular weight of the PEG is
increased.
The osmotic pressure of the polymer-surfactant solution,
which should be minimized to prevent inﬁltration of liquid
into the lung during ARDS treatment, is proportional to Np/V,
so high molecular weight polymers should have a distinct
advantage in treatments of ARDS and other lung injuries.
For example, for 10 kDa PEG, increased lung water reduced
the beneﬁcial effects of the polymer in a rabbit model of
acute lung injury (22). The adverse effects were reversed by
giving the animals a diuretic and using a hypotonic saline
vehicle for administration of the surfactant/PEG mixture
(50,51).
The range of the depletion force is 2Rg (Eq. 13), which
shows that using higher molecular weight polymers will in-
crease the range as well as the magnitude of the depletion
interaction. The range of electrostatic interactions are roughly
k1; the Debye length (26,31,33), which is proportional to
the ionic strength of the subphase. k1 ; 1 nm for 150 mM
physiological saline (33). The charge density of the serum at
the interface likely increases with the surface pressure up to
pmax, so the magnitude of the electrostatic repulsion should
change with surface pressure. It is not known what the range
of the steric interactions with serum components might be.
PEG (4 kDa) has Rg ¼ 2.7 nm, and 6 kDa PEG has Rg ¼
3.3 nm (52), so even relatively small molecular weight poly-
mers should have a sufﬁcient range of depletion forces. Yu
et al. found some effect on surfactant adsorption with 3.3 kDa
PEG (22). PEG (1 kDa) has Rg ¼ 1.3 nm, which may be too
small for depletion forces to overcome electrostatic repul-
sion. Future investigations are needed to determine the mo-
lecular weight and concentration to provide the optimal
osmotic pressure, depletion attraction, and solution viscosity
for clinical formulations.
Larger surfactant aggregates will feel a larger push to the
interface, as the depletion interaction is proportional to the
aggregate radius, R; larger particles also deliver more sur-
factant to the interface. Additional considerations in the
model include the diffusivity of the surfactant aggregates in
the subphase. According to the Stokes-Einstein model for
diffusion of a surfactant aggregate, D ¼ kBT=6phR ; h is
the subphase viscosity, which increases with polymer con-
centration and polymer molecular weight. Hence, there is
likely an optimal combination of polymer concentration and
molecular weight to maximize the rate of surfactant diffusion
to the interface. Yu et al. (22) found that for 300 kDa PEG,
surfactant adsorption was inhibited by the high viscosity of
the PEG solution. The diffusivity is also inversely propor-
tional to the surfactant aggregate radius, R, so there is likely
an upper limit on the optimal surfactant aggregate size.
Survanta aggregates are much larger than Curosurf aggre-
gates, and there is a larger fraction of very small aggregates
in Infasurf (Fig. 2) (53).
Another interesting aspect of the depletion interaction is
the coupling with electrostatic forces. Experimentally, it is
found that if both surfactant aggregates and polymer have the
same charge, then the depletion layer can extend further than
FIGURE 2 Optical microscope images of different clinical surfactants
before (left column) and after (right column) addition of 5 wt%10KPEG. (A)
Curosurf; (B) Curosurf with 5 wt% 10 K PEG. Formation of large ﬂocculates
is obvious in panel B compared to the much smaller particles in panel A. The
depletion interaction between particles is roughly half that between surfactant
particles and the interface, but still sufﬁcient to overcome any thermal or
electrostatic repulsion between the surfactant aggregates. (C) Infasurf; (D)
Infasurf with 5 wt% 10 K PEG. Large, irregular ﬂocs also form for Infasurf,
suggesting that the interaction between the surfactant and polymer does not
depend on the speciﬁc composition of the surfactant as suggested by the
depletion interaction. (E) Survanta. Survanta has larger particles before
polymer addition than either Curosurf or Infasurf. (F) Survanta with 5 wt%
10 K PEG. Survanta exhibits the greatest amount of ﬂocculation on addition
of polymer, consistent with Eq. 13. All the images are consistent with the
entropic depletion interaction forcing the large particles together to maximize
the accessible volume of the polymers.All the commercial surfactants contain
anionic lipids, and hence are negatively charged. The depletion potential is
sufﬁcient to overcome the electrostatic repulsion and the thermal motion that
would otherwise keep the aggregates apart.
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Rg (31). The electrostatic repulsion between the large and
small particles increase the effective radius of both large
and small particles by roughly k1; the Debye length (31) in
Eq. 13, leading to an effective depletion attraction of the
form:
W ¼ 4pNpðR1k1ÞðRg1k1Þ2kBT=V: (15)
In physiological saline, k1 ; 1 nm. Lung surfactant
contains a substantial fraction of anionic lipids, so this sug-
gests that an anionic polymer such as HA might provide a
larger depletion interaction for a given concentration than
a nonionic polymer such as PEG. This may also contribute to
the smaller concentration of HA needed to reverse inhibition
than the uncharged PEG.
CONCLUSIONS
In ARDS, increased concentrations of serum and inﬂamma-
tory proteins in the alveolar hypophase are a likely contrib-
uting factor to the rapid inactivation of lung surfactant.
Albumin concentrations in ARDS alveolar ﬂuids may reach
100 mg/ml, with an average concentration reported by Ishizaka
and co-workers of 25 mg/ml (54). Many of the proteins in
serum reach their saturation surface pressure, pmax, at much
lower concentrations (12,27). For both albumin and ﬁbrin-
ogen, pmax is achieved for concentrations .;0.1 mg/ml
(12), which means that.99% of the albumin typically found
in ARDS alveolar ﬂuid (54) would have to be removed to
eliminate the adsorbed albumin and lower the energy barrier
to surfactant adsorption. Although Wiswell and co-workers
(15) saw improvements in oxygenation after they adminis-
tered large volumes of surfactant by bronchoscope and
removed ;50% of the volume instilled along with large
amounts of serum and inﬂammatory proteins, surfactant in-
activation, and the symptoms of ARDS persisted. It is likely
to be impractical, if not impossible, to physically remove the
inactivating substances in vivo during ARDS therapy.
Reversing surfactant inactivation likely will require re-
storing the rate of surfactant adsorption to normal levels by
lowering the energy barrier as shown in Eq. 11. From the
theory presented here, the rate of surfactant adsorption at
a given surface pressure should increase linearly with the
bulk surfactant concentration (Eq. 11). This is consistent
with the in vitro observations reported in Part 1 and also
found by others (17,22). In vivo, instilling 3–5 times the
concentration of surfactant used to treat NRDS directly by
bronchoscope to the lungs of ARDS patients resulted in
some improvement (13,14). Increasing the available exog-
enous surfactant pool, while at the same time, lowering the
protein load in the alveoli, could improve results for ARDS
patients. However, if sufﬁcient serum protein remains that
the electrostatic and steric barrier to adsorption is of order
10–15 kBT, which is certainly possible given the known
magnitude of electrostatic and steric effects for charged
proteins at the air-liquid interface (29,33), it would be
difﬁcult to increase the concentration sufﬁciently to over-
come inactivation.
According to Eq. 14, a signiﬁcantly greater increase in the
rate of surfactant adsorption can be obtained by lowering the
energy barrier to adsorption by adding hydrophilic polymers
to the surfactant suspension as shown in the companion
article. The added polymers create a depletion attraction
potential that can be of the same order of magnitude as the
electrostatic and steric repulsive potentials (see Eq. 13) and
can easily be adjusted by changing the polymer molecular
weight, charge, and concentration. As the energy barrier is
lowered, the rate of adsorption should increase exponentially.
These results are consistent with the experimental observa-
tions in the companion article and in the literature (3,16–22,
50,51) that PEG, dextran, and HA can reverse surfactant
inactivation both in vivo and in vitro. The model presented
here provides readily testable predictions of the effects of
molecular weight, polymer and surfactant concentration,
polymer charge, and surfactant aggregate size that are quali-
tatively consistent with the results in the companion article.
High molecular weight, anionic polymers should provide the
best results for a given polymer weight fraction, as is observed
in the companion article. Low polymer concentrations will
help minimize the osmotic stress in vivo to minimize com-
plications of ARDS therapy. A systematic study of surfactant
adsorption rates will show that there is an optimal combina-
tion of surfactant structure, polymer charge, molecular weight,
and solution viscosity that can be guided by the theory pre-
sented here to develop new therapies for ARDS treatment.
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